AngioSoma Strengthens IP Position With New Patent Filing
16 oct. 2018 06h00 HE
|
AngioSoma, Inc.
OmniCath™ II Patent Filing Showcases Product Effectiveness Houston, TX, Oct. 16, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading pharmaceutical research and...
New Formula of StemStrength by AngioSoma Inc. Now Available to The Public Online
15 oct. 2018 06h00 HE
|
AngioSoma, Inc.
HOUSTON, TX, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma (OTC: SOAN), a leading biotechnology company, announces today the availability of the anticipated new and improved version...
AngioSoma Unveils New Logo and Brand Identity
11 juil. 2018 14h32 HE
|
AngioSoma, Inc.
Houston, TX., July 11, 2018 (GLOBE NEWSWIRE) -- AngioSoma (OTC: SOAN) today launched a new corporate logo and website, marking the most dramatic change in its visual identity since 2016. Taking a...
AngioSoma Prepares for Final FDA Approval Process on Company's Flagship Biologic
25 juin 2018 09h30 HE
|
AngioSoma, Inc.
HOUSTON, TX, June 25, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN) is in discussions to engage a respected pharmaceutical regulatory advisory firm to help it navigate the Food and Drug...
AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug
18 juin 2018 11h44 HE
|
AngioSoma, Inc.
HOUSTON, TX, June 18, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (SOAN) is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, Liprostin™,...
AngioSoma, Inc. Announces Grant of Patent for Flagship Drug
14 mai 2018 12h13 HE
|
AngioSoma, Inc.
HOUSTON, TX, May 14, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN) is excited to announce that the U.S. Patent Office has agreed to grant our patent application for our flagship...